← All trials
NCT05813912
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2023
- Primary completion
- Sep 3, 2024
- Completion date
- Jul 25, 2025
- First posted
- Apr 14, 2023
- Last posted
- Dec 13, 2023
- Enrollment
- 148
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Novo NordiskLead sponsor
- Novo NordiskStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.